"A precise diagnosis informs the patient's care pathway progress, from screening and diagnosis to treatment, monitoring, assessment, and the transition toward home care," said Kees Wesdorp, Chief Business Leader Precision Diagnosis at Philips. "Philips integrated solutions for oncology, including this latest enhancement in digital pathology, help empower the cancer care team to reach clinical treatment decisions based on richer dashboards, clinical images, reports, and structured patient data. The seamless integration of information into the oncology workflow will help improve the clinician experience and ultimately, patient outcomes."

Philips participation in the Virtual ECP 2020 Congress


Philips will host a virtual presence during the 32nd European Society of Pathology Congress (ECP 2020) from December 6-8. ECP attendees will experience digital pathology imaging through demonstrations and webinars. Dr. Juan Retamero, a digital pathology professional, will share his experiences and vision on how digital pathology brings great potential to enhance patient care.


About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries.

Back to HCB News

Rad Oncology Homepage